| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1111064098 |
| P356 | DOI | 10.1186/S12967-018-1756-4 |
| P932 | PMC publication ID | 6317198 |
| P698 | PubMed publication ID | 30602367 |
| P50 | author | Ying-Yong Zhao | Q56994979 |
| Nosratola D Vaziri | Q114400165 | ||
| P2093 | author name string | Lin Chen | |
| Yan Guo | |||
| Yuan-Yuan Chen | |||
| Jing-Ru Liu | |||
| Dan-Qian Chen | |||
| P2860 | cites work | Contributory Role of Gut Microbiota and Their Metabolites Toward Cardiovascular Complications in Chronic Kidney Disease. | Q51732046 |
| Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins. | Q53703242 | ||
| Dietary L-Tryptophan Modulates the Structural and Functional Composition of the Intestinal Microbiome in Weaned Piglets | Q58797378 | ||
| Protein-bound Uremic Toxins, Inflammation and Oxidative Stress: A Cross-sectional Study in Stage 3–4 Chronic Kidney Disease | Q61523770 | ||
| Dietary protein-fiber ratio associates with circulating levels of indoxyl sulfate and p-cresyl sulfate in chronic kidney disease patients | Q62084625 | ||
| Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis | Q71728826 | ||
| Hemodialysis | Q82292918 | ||
| Effect of a symbiotic gel (Lactobacillus acidophilus + Bifidobacterium lactis + inulin) on presence and severity of gastrointestinal symptoms in hemodialysis patients | Q86125174 | ||
| Diuretic activity of the ethanol and aqueous extracts of the surface layer of Poria cocos in rat | Q87432279 | ||
| Chronic kidney disease, uremic milieu, and its effects on gut bacterial microbiota dysbiosis | Q88468649 | ||
| Natural Products as a Source for Antifibrosis Therapy | Q91881550 | ||
| Natural products for the prevention and treatment of kidney disease | Q93357156 | ||
| Prebiotics: why definitions matter | Q26782558 | ||
| The Gut as a Source of Inflammation in Chronic Kidney Disease | Q28081781 | ||
| A metagenomic insight into our gut's microbiome | Q28265135 | ||
| The role of Oxalobacter formigenes colonization in calcium oxalate stone disease | Q28287913 | ||
| Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function | Q28511055 | ||
| Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms | Q28742033 | ||
| Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy | Q30234704 | ||
| The ribosomal database project (RDP-II): introducing myRDP space and quality controlled public data | Q31074822 | ||
| Gut microbiome and kidney disease: a bidirectional relationship | Q33586234 | ||
| Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target | Q33613115 | ||
| Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients | Q33684162 | ||
| Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. | Q33725646 | ||
| Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). | Q33748498 | ||
| Alteration of the gut microbiota in Chinese population with chronic kidney disease | Q33767631 | ||
| Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients | Q34043268 | ||
| Serum metabonomics study of adenine-induced chronic renal failure in rats by ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry | Q34088508 | ||
| Real-time PCR analysis of the intestinal microbiotas in peritoneal dialysis patients. | Q34104678 | ||
| Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients | Q34124697 | ||
| Effect of ergosta-4,6,8(14),22-tetraen-3-one (ergone) on adenine-induced chronic renal failure rat: a serum metabonomic study based on ultra performance liquid chromatography/high-sensitivity mass spectrometry coupled with MassLynx i-FIT algorithm. | Q34300276 | ||
| Melamine-induced renal toxicity is mediated by the gut microbiota | Q34327763 | ||
| Ultra performance liquid chromatography-based metabonomic study of therapeutic effect of the surface layer of Poria cocos on adenine-induced chronic kidney disease provides new insight into anti-fibrosis mechanism | Q34651679 | ||
| High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease | Q34663426 | ||
| Gut dysbiosis is linked to hypertension. | Q34669297 | ||
| Dietary protein metabolism by gut microbiota and its consequences for chronic kidney disease patients. | Q34995574 | ||
| The gut microbiome, kidney disease, and targeted interventions | Q35042986 | ||
| Review on uremic toxins: classification, concentration, and interindividual variability | Q35098883 | ||
| UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry | Q35217999 | ||
| Alterations of intestinal barrier and microbiota in chronic kidney disease. | Q35239148 | ||
| Salivary Microbiota Associated with Immunoglobulin A Nephropathy. | Q35575663 | ||
| Gut microbiome in chronic kidney disease | Q35764101 | ||
| Lipidomics: Novel insight into the biochemical mechanism of lipid metabolism and dysregulation-associated disease. | Q35769873 | ||
| The Influence of CKD on Colonic Microbial Metabolism | Q35786047 | ||
| Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial. | Q35895422 | ||
| Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress, inflammation, fibrosis, and Nrf2 dysfunction in aristolochic acid-induced nephropathy | Q35926121 | ||
| Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers. | Q35999340 | ||
| Gut microbiota, metabolites and host immunity | Q36031926 | ||
| Role of Gastrointestinal Microbiota on Kidney Injury and the Obese Condition | Q36254699 | ||
| Enterobacteriaceae peritonitis complicating peritoneal dialysis: a review of 210 consecutive cases. | Q36391814 | ||
| An integrated lipidomics and metabolomics reveal nephroprotective effect and biochemical mechanism of Rheum officinale in chronic renal failure. | Q36606173 | ||
| Resistant starch alters gut microbiome and metabolomic profiles concurrent with amelioration of chronic kidney disease in rats | Q36902202 | ||
| Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease | Q36940342 | ||
| Mechanism of cytokine modulation of epithelial tight junction barrier | Q37047106 | ||
| Uremic plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium | Q37050237 | ||
| CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity | Q37131182 | ||
| Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study | Q37263314 | ||
| Hyperoxaluria leads to dysbiosis and drives selective enrichment of oxalate metabolizing bacterial species in recurrent kidney stone endures | Q37314836 | ||
| Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism | Q37318311 | ||
| A critical analysis of the role of gut Oxalobacter formigenes in oxalate stone disease | Q37330510 | ||
| Metabolomics insights into activated redox signaling and lipid metabolism dysfunction in chronic kidney disease progression. | Q37343636 | ||
| Gut microbiota dysbiosis contributes to the development of hypertension. | Q37618646 | ||
| Regulation of tight junction permeability by intestinal bacteria and dietary components | Q37856589 | ||
| Metabolomics in chronic kidney disease | Q38097571 | ||
| UPLC-MS(E) application in disease biomarker discovery: the discoveries in proteomics to metabolomics | Q38196105 | ||
| Ultra-performance liquid chromatography-mass spectrometry as a sensitive and powerful technology in lipidomic applications | Q38228422 | ||
| Metabolomics in nephrotoxicity. | Q38252338 | ||
| Metabolomics in dyslipidemia. | Q38262695 | ||
| Lipidomics applications for discovering biomarkers of diseases in clinical chemistry | Q38265745 | ||
| Lipidomics applications for disease biomarker discovery in mammal models | Q38358769 | ||
| Lipidomics: new insight into kidney disease. | Q38413786 | ||
| Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. | Q38425357 | ||
| Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: a randomized clinical trial. | Q38428422 | ||
| Metabolomic application in toxicity evaluation and toxicological biomarker identification of natural product. | Q38797231 | ||
| Gut microbiome and lipid metabolism: from associations to mechanisms | Q38800638 | ||
| Gut microbiome in chronic kidney disease: challenges and opportunities | Q38836354 | ||
| Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials | Q38846496 | ||
| The Role of the Gut Microbiome on Chronic Kidney Disease. | Q38938184 | ||
| Increasing rigor in NMR-based metabolomics through validated and open source tools | Q38958453 | ||
| The intestinal epithelial barrier: a therapeutic target? | Q39009998 | ||
| Gut hormones and gut microbiota: implications for kidney function and hypertension | Q39014336 | ||
| Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention | Q39184442 | ||
| Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease | Q39227281 | ||
| Metabolomics highlights pharmacological bioactivity and biochemical mechanism of traditional Chinese medicine | Q39376390 | ||
| The impact of gut microbiota on kidney function and pathogenesis. | Q39400976 | ||
| Trimethylamine N-Oxide, the Microbiome, and Heart and Kidney Disease | Q39439313 | ||
| Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation | Q39598955 | ||
| Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease | Q42933107 | ||
| p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. | Q43289498 | ||
| Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study | Q43321758 | ||
| UPLC-Q-TOF/HSMS/MS(E)-based metabonomics for adenine-induced changes in metabolic profiles of rat faeces and intervention effects of ergosta-4,6,8(14),22-tetraen-3-one | Q45808017 | ||
| Combined Clinical Phenotype and Lipidomic Analysis Reveals the Impact of Chronic Kidney Disease on Lipid Metabolism. | Q45980858 | ||
| Chronic kidney disease alters intestinal microbial flora | Q46042782 | ||
| Metabolomic Signatures of Chronic Kidney Disease of Diverse Etiologies in the Rats and Humans. | Q46053853 | ||
| Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction | Q46078911 | ||
| Urea and impairment of the Gut-Kidney axis in Chronic Kidney Disease | Q46247658 | ||
| Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug | Q46362610 | ||
| The link between phenotype and fatty acid metabolism in advanced chronic kidney disease. | Q46397367 | ||
| A new era in the treatment of calcium oxalate stones? | Q46419423 | ||
| Indoxyl sulfate enhances IL-1β-induced E-selectin expression in endothelial cells in acute kidney injury by the ROS/MAPKs/NFκB/AP-1 pathway | Q46624915 | ||
| Removal of uremic retention products by hemodialysis is coupled with indiscriminate loss of vital metabolites | Q46939699 | ||
| The Gut Microbiota Facilitates Drifts in the Genetic Diversity and Infectivity of Bacterial Viruses | Q47415707 | ||
| An Integrated Lipidomics and Phenotype Study Reveals Protective Effect and Biochemical Mechanism of Traditionally Used Alisma orientale Juzepzuk in Chronic Kidney Disease. | Q50326733 | ||
| Is there a relationship between tryptophan dietary intake and plasma levels of indoxyl sulfate in chronic kidney disease patients on hemodialysis? | Q51245332 | ||
| Protein-Bound Uremic Toxins from Gut Microbiota and Inflammatory Markers in Chronic Kidney Disease. | Q51383478 | ||
| p-cresol but not p-cresyl sulfate stimulate MCP-1 production via NF-κB p65 in human vascular smooth muscle cells. | Q51628686 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | kidney disease | Q1054718 |
| microbiome | Q1330402 | ||
| kidney | Q9377 | ||
| P304 | page(s) | 5 | |
| P577 | publication date | 2019-01-03 | |
| P1433 | published in | Journal of Translational Medicine | Q15716664 |
| P1476 | title | Microbiome-metabolome reveals the contribution of gut-kidney axis on kidney disease | |
| P478 | volume | 17 |
| Q93129177 | Aryl hydrocarbon receptor activation mediates kidney disease and renal cell carcinoma |
| Q104141493 | Associations between untargeted plasma metabolomic signatures and gut microbiota composition in the Milieu Intérieur population of healthy adults |
| Q92178276 | Blood Pressure Abnormalities Associated with Gut Microbiota-Derived Short Chain Fatty Acids in Children with Congenital Anomalies of the Kidney and Urinary Tract |
| Q89861538 | Calcium Oxalate Nephrolithiasis and Gut Microbiota: Not just a Gut-Kidney Axis. A Nutritional Perspective |
| Q92890573 | Combined melatonin and poricoic acid A inhibits renal fibrosis through modulating the interaction of Smad3 and β-catenin pathway in AKI-to-CKD continuum |
| Q89641871 | Constipation in CKD |
| Q91808273 | Dietary Factors in the Control of Gut Homeostasis, Intestinal Stem Cells, and Colorectal Cancer |
| Q92103461 | Dysbiotic gut microbes may contribute to hypertension by limiting vitamin D production |
| Q92343925 | Gut Dysbiosis and the Intestinal Microbiome: Streptococcus thermophilus a Key Probiotic for Reducing Uremia |
| Q94562212 | Integrative metagenomic and metabolomic analyses reveal severity-specific signatures of gut microbiota in chronic kidney disease |
| Q89989584 | Lactobacillus salivarius BP121 prevents cisplatin‑induced acute kidney injury by inhibition of uremic toxins such as indoxyl sulfate and p‑cresol sulfate via alleviating dysbiosis |
| Q97543628 | NAFLD in type 2 diabetes mellitus - still many challenging questions |
| Q98159561 | Progress in Pathogenesis of Immunoglobin A Nephropathy |
| Q119622901 | The Gut Microbiome Composition Is Altered in Long-standing Type 1 Diabetes and Associates With Glycemic Control and Disease-Related Complications |
| Q64111295 | Unilateral ureteral obstruction causes gut microbial dysbiosis and metabolome disorders contributing to tubulointerstitial fibrosis |
Search more.